German groups take aim at AMNOG

Five German medical societies criticized the early benefit assessment process under drug pricing law AMNOG, saying that conclusions by the Institute for Quality and Efficiency in Healthcare (IQWiG) "not infrequently" deviate from current treatment standards. The groups also said comparator therapies selected by Germany's Federal Joint Committee (G-BA) are often "unfitting" and contrary to current medical knowledge. In a statement, G-BA Chairman Josef Hecken said the arguments were "in no way convincing." ...